WO2023005911A1 - 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用 - Google Patents

一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用 Download PDF

Info

Publication number
WO2023005911A1
WO2023005911A1 PCT/CN2022/107875 CN2022107875W WO2023005911A1 WO 2023005911 A1 WO2023005911 A1 WO 2023005911A1 CN 2022107875 W CN2022107875 W CN 2022107875W WO 2023005911 A1 WO2023005911 A1 WO 2023005911A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
vitamin
nucleotide
compound
nucleotides
Prior art date
Application number
PCT/CN2022/107875
Other languages
English (en)
French (fr)
Inventor
李勇
徐美虹
陈玉松
曾峥
Original Assignee
陈玉松
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈玉松 filed Critical 陈玉松
Publication of WO2023005911A1 publication Critical patent/WO2023005911A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the field of medicine and health care, and specifically relates to a nucleotide composition for auxiliary treatment of diabetes and its preparation method and application.
  • Diabetes is a metabolic disease characterized by high blood sugar. Hyperglycemia is caused by defective insulin secretion or impaired biological action, or both. Insulin is a protein hormone secreted by the islet ⁇ cells in the pancreas stimulated by endogenous or exogenous substances such as glucose, lactose, ribose, arginine, glucagon, etc. Hormone of blood sugar, while promoting the synthesis of glycogen, fat and protein.
  • Nucleotide is the basic unit of ribonucleic acid and deoxyribonucleic acid, and is the precursor of nucleic acid synthesis in vivo. Nucleotides are distributed in the nucleus and cytoplasm of various organs, tissues, and cells in the organism along with nucleic acids, and have important biological functions. They participate in almost all biochemical reaction processes in the organism. The regulation of insulin secretion is closely related to the metabolism of various nucleotides in ⁇ cells. When insulin is secreted, various nucleotides in the cytoplasm also affect insulin secretion. Adenosine triphosphate (ATP) plays a key role in the regulation of insulin secretion from ⁇ cells.
  • ATP adenosine triphosphate
  • adenosine is also several important coenzymes, such as coenzyme I (nicotinamide adenine dinucleotide, NAD+), coenzyme II (nicotinamide adenine dinucleotide phosphate, NADP+), flavin adenine dinucleotide NAD+ can promote the secretion of insulin, so as to supplement the insufficient secretion of insulin in diabetic patients.
  • nucleotides play an important role in maintaining the immune function of the body, promoting the proliferation of immune cells and the secretion of cytokines. Supplementing nucleotides can improve the body's immune function and enhance the body's immunity. In the past two decades, exogenous nucleotides have been widely used in infant formula milk powder and health products, and their safety in human body has been fully proved by scientific experiments.
  • CN 201880051788.5 discloses a composition and method for treatment using nicotinamide mononucleotide, including that the composition containing nicotinamide mononucleotide can be used to treat, improve, alleviate or reverse any disease involving NMN metabolism or disorders, eg, diabetes, obesity, decreased insulin sensitivity, impairment of glucose-stimulated insulin secretion, and the like.
  • the object of the present invention is to provide a nucleotide composition for auxiliary treatment of diabetes, its preparation method and application.
  • the compound nucleotide is a mixture composed of AMP, CMP, GMP, and UMP four mononucleotides in a certain proportion, which can be combined with vitamins, minerals and other nutrients or functional substances (ingredients), which can play a role in auxiliary treatment , Improve the role of diabetes.
  • a nucleotide composition for the auxiliary treatment of diabetes includes compound nucleotides composed of four mononucleotides of AMP, CMP, GMP, and UMP, wherein the weight of the compound nucleotides The ratio is: AMP 15.0-25.0%, CMP 15.0-45.0%, GMP 15.0-35.0%, UMP 15.0-30.0%.
  • nucleotide composition also includes vitamins, minerals and other nutrients or functional substances (ingredients), and compound nucleotides are matched with vitamins, minerals and other nutrients or functional substances (ingredients) to form a composition , play a synergistic effect;
  • the ratio of the compound nucleotides to vitamins, minerals and other nutrients is: 8-232 parts of compound nucleotides, 0.16-0.9 parts of vitamin A, 0.003-0.012 parts of vitamin D, 3.18-7.15 parts of vitamin E, Vitamin K 1 0.018-0.04 parts, vitamin B 1 0.34-0.76 parts, vitamin B 2 0.34-0.76 parts, vitamin B 6 0.34-0.76 parts, vitamin B 12 0.0005-0.0011 parts, niacin 0.84-1.89 parts, folic acid 0.089- 0.2 parts, pantothenic acid 1.17-2.63 parts, vitamin C 21.76-48.96 parts, biotin 0.008-0.019 parts, sodium 334.71-522.99 parts, potassium 451.86-706.04 parts, copper 0.18-2 parts, magnesium 73.64-115.06 parts, iron 3.3- 9.2 parts, zinc 1.67-8.36 parts, manganese 0.1-2.44 parts, calcium 217.56-339.94 parts, phosphorus 160.67-251.04 parts, iodine
  • Another object of the present invention is to provide a method for preparing the above compound nucleotide composition.
  • Each component is weighed according to the formula, mixed uniformly and prepared into a finished product according to a conventional process.
  • the finished product state includes powder, granule, tablet, pill, oral liquid and capsule.
  • Another object of the present invention is to provide the application of the above nucleotide composition in the preparation of products for the auxiliary treatment of diabetes.
  • the finished product of the nucleotide composition can be directly or added to medicines, food for special medical purposes, health products and functional food after being processed through conventional steps, so as to play an auxiliary role in treating diabetes.
  • the present invention provides a nucleotide composition for the auxiliary treatment of diabetes, including compound nucleotides composed of four mononucleotides of AMP, CMP, GMP and UMP, or compound core A mixture made of glycosides and nutrients such as vitamins and minerals or functional substances (ingredients).
  • the nucleotide composition After the nucleotide composition is ingested by the human body, it will be decomposed into various free nucleotide substances under the action of various enzymes in the human digestive tract, which can promote the secretion of insulin and increase the immunity of the human body, thereby achieving adjuvant therapy
  • Nucleotides are food additives, and their safety in human body has been fully proved by scientific experiments.
  • a kind of preparation method of compound nucleotide is as follows:
  • the compound nucleotides are formulated according to AMP 16.9wt%, CMP 43.2wt%, GMP 17.8wt%, and UMP 22.1wt%. After conversion, the raw materials are weighed and mixed evenly with a mixer to obtain a powder. The above operations are all carried out in a clean area, and samples are taken according to the quality standards for inspection of various indicators.
  • the compound nucleotides are formulated according to AMP 24.3wt%, CMP 28.3wt%, GMP 19.3wt%, and UMP 28.1wt%. After conversion, the raw materials are weighed and mixed evenly with a mixer to obtain a powder. The above operations are all carried out in a clean area, and samples are taken according to the quality standards for inspection of various indicators.
  • a preparation method of compound nucleotide composition is as follows:
  • Each 100g contains Compound nucleotide/(mg) 84.44 Vitamin A/( ⁇ g RE) 194.55 Vitamin D/( ⁇ g) 3.97 Vitamin E/(mg ⁇ -TE) 3.97 Vitamin K 1 /( ⁇ g) 21.97 Vitamin B 1 /(mg) 0.42 Vitamin B 2 /(mg) 0.42 Vitamin B 6 /(mg) 0.42 Vitamin B 12 /( ⁇ g) 0.63 Niacin/(mg) 1.05 Folic acid/( ⁇ g) 110.87 Pantothenic acid/(mg) 1.46 Vitamin C/(mg) 27.20 Biotin/( ⁇ g) 10.46 Sodium/(mg) 418.39 Potassium/(mg) 564.83 Copper/( ⁇ g) 230.11 Magnesium/(mg) 92.05
  • a certain amount of raw materials are weighed after conversion, and mixed evenly with a mixer to obtain a powder.
  • the above operations are all carried out in a clean area, and the finished products are sampled according to the quality standards for inspection of various indicators.
  • a preparation method of compound nucleotide composition is as follows:
  • Each 100g contains Compound nucleotide/(mg) 128.89 Vitamin A/( ⁇ g RE) 194.55 Vitamin D/( ⁇ g) 3.97 Vitamin E/(mg ⁇ -TE) 3.97 Vitamin K 1 /( ⁇ g) 21.97 Vitamin B 1 /(mg) 0.42 Vitamin B 2 /(mg) 0.42 Vitamin B 6 /(mg) 0.42 Vitamin B 12 /( ⁇ g) 0.63 Niacin/(mg) 1.05 Folic acid/( ⁇ g) 110.87 Pantothenic acid/(mg) 1.46 Vitamin C/(mg) 27.20 Biotin/( ⁇ g) 10.46 Sodium/(mg) 418.39 Potassium/(mg) 564.83 Copper/( ⁇ g) 230.11 Magnesium/(mg) 92.05 Iron/(mg) 4.18 Zinc/(mg) 2.09
  • the compound nucleotides in this example are the compound nucleotides prepared in Example 2.
  • a preparation method of compound nucleotide composition is as follows:
  • Each 100g contains Compound nucleotide/(mg) 84.44 Vitamin A/( ⁇ g RE) 194.55 Vitamin D/( ⁇ g) 3.97 Vitamin E/(mg ⁇ -TE) 3.97 Vitamin K 1 /( ⁇ g) 21.97 Vitamin B 1 /(mg) 0.42 Vitamin B 2 /(mg) 0.42 Vitamin B 6 /(mg) 0.42 Vitamin B 12 /( ⁇ g) 0.63 Niacin/(mg) 1.05 Folic acid/( ⁇ g) 110.87 Pantothenic acid/(mg) 1.46 Vitamin C/(mg) 27.20 Biotin/( ⁇ g) 10.46 Sodium/(mg) 418.39 Potassium/(mg) 564.83 Copper/( ⁇ g) 230.11 Magnesium/(mg) 92.05 Iron/(mg) 4.18
  • the compound nucleotides in this example are the compound nucleotides prepared in Example 1.
  • a certain amount of raw materials are weighed after conversion, and mixed evenly with a mixer to obtain a powder.
  • the above operations are all carried out in a clean area, and the finished products are sampled according to the quality standards for inspection of various indicators.
  • compound nucleotide the compound nucleotide prepared in embodiment 2
  • resistant dextrin 6.5g
  • protolinolenic acid microcapsule powder linseed oil microcapsule powder
  • taurine 0.5 g
  • a preparation method of compound nucleotide composition is as follows:
  • compound nucleotide prepared compound nucleotide in embodiment 2
  • resistant dextrin 6.5g
  • taurine 0.5 part
  • tangerine peel extract tangerine peel extract
  • Embodiment 8 Effect experiment example
  • Experimental dose 45mg/kgBW for the low-dose nucleotide group, 90mg/kgBW for the medium-dose nucleotide group and 135mg/kgBW for the high-dose nucleotide group, mixed with distilled water to the required concentration; combined drug dose 0.1U/kg Add 45mg/kgBW of low-dose nucleotide group, 90mg/kgBW of medium-dose nucleotide group and 135mg/kgBW of high-dose nucleotide group.
  • mice Using alloxan to induce insulin resistance and glucose metabolism disorder model to conduct hyperglycemia model hypoglycemic experiments on mice (alloxan is a kind of islet ⁇ cell toxic agent, which can generate free radicals and selectively attack islet ⁇ cells, resulting in insulin secretion It can also affect other organs, such as the liver, so that the functions of liver glycogen synthesis and glucose utilization are inhibited, thus causing experimental diabetes).
  • mouse fasting blood glucose and glucose tolerance were used as judgment indexes.
  • mice Healthy male mice were selected, and the experimental mice were divided into three groups, the blank control group (for judging whether the model was successfully established), the control group and the test group.
  • a mouse model of diabetes was constructed, and the mice in the latter two groups were fasted for 12 hours, and injected with 45 mg/kgBW alloxan saline solution intraperitoneally for several days. The build was successful.
  • the successfully constructed alloxan hyperglycemia model was divided into 1 model control group and 7 test groups, and each test group was divided into three groups, namely low-dose nucleotide group, medium-dose nucleotide group and Nucleotide high dose group, model control group and 10 rats in each group.
  • the normal saline solution of the compound nucleotide of the embodiment 1-7 formula of the test group mice is fed with a certain dose every day, respectively 45mg/kgBW of the nucleotide low-dose group, 90mg/kgBW of the nucleotide middle-dose group And nucleotide high dose group 135mg/kgBW.
  • the remaining two groups (blank control group and model control group) were given intragastric administration of the same amount of normal saline solution every day.
  • the tail blood was taken to measure the fasting blood glucose and insulin content of the mice, and 2.0g/m2 was given to the mice in each group. kgBW glucose solution, the tail blood was taken after 0.5h and 2h respectively to measure the fasting blood glucose of the mice for the glucose tolerance test.
  • Each experimental group was divided into three groups, respectively These are low-dose nucleotide group, middle-dose nucleotide group and high-dose nucleotide group, model control group, insulin treatment group, and 10 rats in each group.
  • the normal saline solution+insulin of the compound nucleotide of the embodiment 2,4,6,7 formula of the experiment group mice is gavaged with a certain dose every day, respectively is nucleotide low dosage group 45mg/kgBW+insulin combined medication, The combination of 90mg/kgBW+insulin in the nucleotide medium dose group and 135mg/kgBW+insulin in the high nucleotide dose group.
  • the blank control group and the model control group were intragastrically administered the same amount of normal saline solution every day, and the insulin treatment group was intragastrically administered the same dose of insulin in combination with nucleotide mixture + insulin (only insulin was added, no nucleotide mixture) After 30 days, the tail blood was taken to measure the fasting blood glucose and insulin levels of the mice.
  • nucleotide mixture in Examples 1-7 has no significant difference on the fasting blood glucose of normal mice, indicating that the nucleotide mixture has no effect on the fasting blood glucose of normal mice.
  • the fasting blood glucose value of the model control group significantly increased (P ⁇ 0.05), indicating that the hyperglycemia model was established;
  • the mixture significantly increased the fasting serum insulin content of hyperglycemia model mice, and significantly decreased the blood sugar value (P ⁇ 0.05), indicating that the nucleotide mixture can promote the secretion of insulin and play a role in lowering blood sugar.
  • each dose of nucleotide mixture and insulin in combination has a significant effect on fasting insulin content in hyperglycemia model mice.
  • Significantly increased and blood sugar decreased P ⁇ 0.05; indicating that while the injected insulin lowers blood sugar, the nucleotide mixture can also promote the secretion of insulin, and the nucleotide mixture and insulin play a synergistic role in lowering blood sugar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用。该复配核苷酸是由AMP、CMP、GMP、UMP四种单核苷酸组成的混合物。其可以与维生素、矿物质等营养素或其他功能性物质(成分)搭配应用于药品、特医食品、保健品和功能性食品，可以改善机体糖耐量，促进胰岛素分泌，起到降血糖的作用。

Description

一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用 技术领域
本发明属于医药保健领域，具体为一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用。
背景技术
糖尿病是一种以高血糖为特征的代谢性疾病。高血糖则是由于胰岛素分泌缺陷或其生物作用受损或两者兼有引起。胰岛素是由胰脏内的胰岛β细胞受内源性或外源性物质如葡萄糖、乳糖、核糖、精氨酸、胰高血糖素等的刺激而分泌的一种蛋白质激素，是机体内唯一降低血糖的激素，同时促进糖原、脂肪、蛋白质合成。
核苷酸是核糖核酸及脱氧核糖核酸的基本组成单位，是体内合成核酸的前身物。核苷酸随着核酸分布于生物体内各器官、组织、细胞的核及胞质中，具有重要的生物学功能，它们参与了生物体内几乎所有的生物化学反应过程。胰岛素分泌的调控与β细胞内的多种核苷酸代谢息息相关，胰岛素分泌时细胞质中多种核苷酸类物质同时对胰岛素分泌产生影响。三磷酸腺苷(ATP)在β细胞分泌胰岛素调控中起关键性作用。同时，腺苷酸还是几种重要辅酶，如辅酶Ⅰ(烟酰胺腺嘌呤二核苷酸，NAD+)、辅酶Ⅱ(磷酸烟酰胺腺嘌呤二核苷酸，NADP+)、黄素腺嘌呤二核苷酸(FAD)及辅酶A(CoA)的组成成分，NAD+可以促进胰岛素的分泌，从而补充糖尿病患者胰岛素分泌不足的情况。此外，核苷酸对于维持机体免疫功能，促进免疫细胞的增殖和细胞因子的分泌具有重要作用。补充核苷酸可以很好的改善机体免疫功能，提高机体免疫力。近二十年来，外源核苷酸已广泛应用于婴幼儿配方乳粉以及保健品中，其在人体中使用的安全性已得到科学试验的充分证明。
【CN 201880051788.5】公开了一种使用烟酰胺单核苷酸进行治疗的组合物和方法，其中包括含有烟酰胺单核苷酸的组合物可用于治疗、改善、减轻或逆转涉及NMN代谢的任何疾病或病症，例如，糖尿病、肥胖症、胰岛素敏感性的降低、葡萄糖刺激的胰岛素分泌的损伤等。
发明内容
本发明的目的在于提供一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用。该复配核苷酸是由AMP、CMP、GMP、UMP四种单核苷酸按一定比例组成的混合物，可再搭配维生素、矿物质等营养素或功能性物质(成分)，可以起到辅助治疗、改善糖尿病的作用。
为实现上述目的，本发明所采用的技术方案是：
一种辅助治疗糖尿病的核苷酸组合物，所述核苷酸组合物包括由AMP、CMP、GMP、UMP四种单核苷酸组成的复配核苷酸，其中复配核苷酸的重量配比为：AMP 15.0-25.0％、CMP 15.0-45.0％、GMP 15.0-35.0％、UMP 15.0-30.0％。
进一步地，复配核苷酸的重量配比为：AMP 16.9％、CMP 43.2％、GMP 17.8％、UMP 22.1％，或AMP 24.3％、CMP 28.3％、GMP 19.3％、UMP 28.1％。
进一步地，所述核苷酸组合物还包括维生素、矿物质等营养素或功能物质(成分)，将复配核苷酸与维生素、矿物质等营养素或功能物质(成分)搭配，制成组合物，发挥协同作用；
所述复配核苷酸与维生素、矿物质等营养素的配比为：复配核苷酸8-232份、维生素A 0.16-0.9份、维生素D 0.003-0.012份、维生素E 3.18-7.15份、维生素K 10.018-0.04份、维生素B 1 0.34-0.76份、维生素B 20.34-0.76份、维生素B 60.34-0.76份、维生素B 12 0.0005-0.0011份、烟酸0.84-1.89份、叶酸0.089-0.2份、泛酸1.17-2.63份、维生素C 21.76-48.96份、生物素0.008-0.019份、钠334.71-522.99份、钾451.86-706.04份、铜0.18-2份、镁73.64-115.06份、铁3.3-9.2份、锌1.67-8.36份、锰0.1-2.44份、钙217.56-339.94份、磷160.67-251.04份、碘0.027-0.042份、氯251.03-870.25份、硒0.013-0.089份，所述营养素还包括铬、牛磺酸、膳食纤维中的一种或多种，铬0.0067-0.2228份、牛磺酸32.2-80.4份、膳食纤维5023-18846份；
或所述复配核苷酸与功能性物质(成分)配比为：复配核苷酸1-3份、功能性物质(成分)5-15份，所述功能性物质为川陈皮提取物(川陈皮素)、亚麻酸微囊粉、抗性糊精中的一种或多种。
本发明的另一目的在于提供上述复配核苷酸组合物的制备方法，将各组分按配方进行称量，混合均匀后按照常规工艺制备成成品。
进一步地，所述成品状态包括粉剂、颗粒剂、片剂、丸剂、口服液、胶囊。
本发明的再一目的在于提供上述核苷酸组合物在制备辅助治疗糖尿病的产品上的应用。所述核苷酸组合物成品可以直接或经常规步骤处理后添加在药品、特医食品、保健品和功能性食品中，起到辅助治疗糖尿病的作用。
本发明的有益效果为：本发明提供了一种辅助治疗糖尿病的核苷酸组合物，包括由AMP、CMP、GMP、UMP四种单核苷酸组成的复配核苷酸，或复配核苷酸与维生素、矿物质等营养素或功能性物质(成分)配伍制成的混合物。该核苷酸组合物被人体摄入以后，在人体消化道内各种酶的作用下分解成各种游离核苷酸类物质，促进胰岛素的分泌，还可以增加人体的免疫力，从而达到辅助治疗糖尿病的作用。核苷酸是食品添加剂类物质，其在人体中使用的安全性已得到科学试验的充分证明。
具体实施方式
下面结合具体实施例对本发明的作进一步解释说明，这些实施例应被理解为仅是举例说明，而非以任何方式限制本发明的范围。
实施例1
一种复配核苷酸的制备方法如下：
复配核苷酸按照AMP 16.9wt％、CMP 43.2wt％、GMP 17.8wt％、UMP 22.1wt％配比，换算后称取原料，用混合机混合均匀，制得粉剂。以上操作均在洁净区进行操作，按质量标准的规定取样进行各项指标的检验。
实施例2
一种复配核苷酸的制备方法如下：
复配核苷酸按照AMP 24.3wt％、CMP 28.3wt％、GMP 19.3wt％、UMP 28.1wt％配比，换算后称取原料，用混合机混合均匀，制得粉剂。以上操作均在洁净区进行操作，按质量标准的规定取样进行各项指标的检验。
实施例3
一种复配核苷酸组合物的制备方法如下：
营养素名称 每100g含
复配核苷酸/(mg) 84.44
维生素A/(μg RE) 194.55
维生素D/(μg) 3.97
维生素E/(mgɑ-TE) 3.97
维生素K 1/(μg) 21.97
维生素B 1/(mg) 0.42
维生素B 2/(mg) 0.42
维生素B 6/(mg) 0.42
维生素B 12/(μg) 0.63
烟酸/(mg) 1.05
叶酸/(μg) 110.87
泛酸/(mg) 1.46
维生素C/(mg) 27.20
生物素/(μg) 10.46
钠/(mg) 418.39
钾/(mg) 564.83
铜/(μg) 230.11
镁/(mg) 92.05
铁/(mg) 4.18
锌/(mg) 2.09
锰/(μg) 125.52
钙/(mg) 271.95
磷/(mg) 200.83
碘/(μg) 33.47
氯/(mg) 334.71
硒/(μg) 16.74
大豆膳食纤维粉/(g) 10.47
药学上可接受的辅料 余量
本实施例中的复配核苷酸为实施例2中制得的复配核苷酸。
按照以上复配核苷酸与营养素、矿物质等营养素的配比，换算后称取一定量的原料，用混合机混合均匀，制得粉剂。以上操作均在洁净区进行操作，成品按质量标准的规定取样进行各项指标的检验。
实施例4
一种复配核苷酸组合物的制备方法如下：
营养素名称 每100g含
复配核苷酸/(mg) 128.89
维生素A/(μg RE) 194.55
维生素D/(μg) 3.97
维生素E/(mgɑ-TE) 3.97
维生素K 1/(μg) 21.97
维生素B 1/(mg) 0.42
维生素B 2/(mg) 0.42
维生素B 6/(mg) 0.42
维生素B 12/(μg) 0.63
烟酸/(mg) 1.05
叶酸/(μg) 110.87
泛酸/(mg) 1.46
维生素C/(mg) 27.20
生物素/(μg) 10.46
钠/(mg) 418.39
钾/(mg) 564.83
铜/(μg) 230.11
镁/(mg) 92.05
铁/(mg) 4.18
锌/(mg) 2.09
锰/(μg) 125.52
钙/(mg) 271.95
磷/(mg) 200.83
碘/(μg) 33.47
氯/(mg) 334.71
硒/(μg) 16.74
铬/(μg) 13.4
牛磺酸/(mg) 40.2
大豆膳食纤维粉/(g) 10.47
药学上可接受的辅料 余量
本实施例中的复配核苷酸为实施例2中制得的复配核苷酸。
按照以上复配核苷酸与营养素、矿物质等营养素的配比，换算后称取一定量的原料，用混合机混合均匀，制得粉剂、片剂或胶囊。以上操作均在洁净区进行操作，成品按质量标准的规定取样进行各项指标的检验。
实施例5
一种复配核苷酸组合物的制备方法如下：
营养素名称 每100g含
复配核苷酸/(mg) 84.44
维生素A/(μg RE) 194.55
维生素D/(μg) 3.97
维生素E/(mgɑ-TE) 3.97
维生素K 1/(μg) 21.97
维生素B 1/(mg) 0.42
维生素B 2/(mg) 0.42
维生素B 6/(mg) 0.42
维生素B 12/(μg) 0.63
烟酸/(mg) 1.05
叶酸/(μg) 110.87
泛酸/(mg) 1.46
维生素C/(mg) 27.20
生物素/(μg) 10.46
钠/(mg) 418.39
钾/(mg) 564.83
铜/(μg) 230.11
镁/(mg) 92.05
铁/(mg) 4.18
锌/(mg) 2.09
锰/(μg) 125.52
钙/(mg) 271.95
磷/(mg) 200.83
碘/(μg) 33.47
氯/(mg) 334.71
硒/(μg) 16.74
大豆膳食纤维粉/(g) 7.87
药学上可接受的辅料 余量
本实施例中的复配核苷酸为实施例1中制备得到的复配核苷酸。
按照以上复配核苷酸与营养素、矿物质等营养素的配比，换算后称取一定量的原料，用混合机混合均匀，制得粉剂。以上操作均在洁净区进行操作，成品按质量标准的规定取样进行各项指标的检验。
实施例6
一种复配核苷酸组合物的制备方法如下：
按照复配核苷酸(实施例2中制备得到的复配核苷酸)1.2g、抗性糊精6.5g、原亚麻酸微囊粉(亚麻籽油微囊粉)6g、牛磺酸0.5g的配比，称取原料，用混合机混合均匀，制成片剂。以上操作均在洁净区进行操作，成品按质量标准的规定取样进行各项指标的检验。
实施例7
一种复配核苷酸组合物的制备方法如下：
按照复配核苷酸(实施例2中制备得到复配核苷酸)2.4g、抗性糊精6.5g、牛磺酸0.5份、川陈皮提取物(川陈皮素)0.034g的配比，称取原料，用混合机混合均匀，装成胶囊。以上操作均在洁净区进行操作，成品按质量标准的规定取样进行各项指标的检验。
实施例8效果实验例
一、材料与方法
1、样品：上述实施例1-7中所得的核苷酸混合物样品。
2、实验动物
SPF级昆明种小鼠，20g左右，实验温度：24-26℃，湿度65-70％。
3、实验剂量：核苷酸低剂量组45mg/kgBW、核苷酸中剂量组90mg/kgBW和核苷酸高剂量组135mg/kgBW，用蒸馏水配至所需浓度；联合用药剂量0.1U/kg加上核苷酸低剂量组45mg/kgBW、核苷酸中剂量组90mg/kgBW和核苷酸高剂量组135mg/kgBW。
4、实验方法
(1)核苷酸混合物对正常小鼠降糖试验
选用健康雄性小鼠，禁食不禁水12h，取尾血测血糖值，按血糖水平随机分为两组，1个对照组和1个核苷酸高剂量组，每组10只，核苷酸高剂量组给予135mg/kgBW，对照组给予蒸馏水，连续灌胃30天，禁食同前，测空腹血糖值，观察受试物对正常动物空腹血糖的影响。
(2)核苷酸混合物对四氧嘧啶高血糖模型小鼠降糖试验及糖耐量试验
利用四氧嘧啶诱导胰岛素抵抗糖代谢紊乱模型对小鼠进行高血糖模型降糖实验(四氧嘧啶是一种胰岛β细胞毒剂，能够产生自由基，并选择性的攻击胰岛β细胞，造成胰岛素分泌降低，从而导致血糖升高，而且还能影响到其他脏器，比如肝脏，使肝脏糖原合成及葡萄糖利用等功能受到抑制，从而引起实验性糖尿病)。采用小鼠空腹血糖以及糖耐量为判断指标。
选用健康雄性小鼠，实验小鼠分为三大组，空白对照组(用于判断模型是否建立成功)、对照组及试验组。首先构建小鼠糖尿病模型，将后两组小鼠禁食不禁水12h，腹腔注射45mg/kgBW四氧嘧啶生理盐水溶液，连续数日，5天后当小鼠空腹血糖达到大于10mmol/L时，模型构建成功。将构建成功的四氧嘧啶高血糖模型分为1个模型对照组及7个试验组，，每个试验组分为三个小组，分别为核苷酸低剂量组、核苷酸中剂量组和核苷酸高剂量组，模型对照组以及每小组分别10只。将试验组小鼠每日灌胃一定剂量的实施例1-7配方的复配核苷酸的生理盐水溶液，分别为核苷酸低剂量组45mg/kgBW、核苷酸中剂量组90mg/kgBW和核苷酸高剂量组135mg/kgBW。其余两组(空白对照组、模型对照组)每日灌胃等量的生理盐水溶液，30d后，取尾血测定小鼠的空腹血糖和胰岛素含量，并给各组小鼠灌胃2.0g/kgBW葡萄糖溶液，分别于0.5h、2h后取尾血测定小鼠的空腹血糖进行糖耐量实验。
(3)联合用药对四氧嘧啶高血糖模型小鼠降糖试验
选用健康雄性小鼠，实验小鼠分为四大组，空白对照组(用于判断模型是否建立成功)、模型对照组、胰岛素治疗组及核苷酸混合物与胰岛素联合用药的试验组。首先构建小鼠糖尿病模型，将后两组小鼠禁食不禁水12h，腹腔注射45mg/kgBW四氧嘧啶生理盐水溶液，连续数日，5天后当小鼠空腹血糖达到大于10mmol/L时，模型构建成功。将构建成功的四氧嘧啶高血糖模型分为1个模型对照组、1个胰岛素治疗组及4个核苷酸混合物与胰岛素联合用药组的试验组，每个试验组分为三个小组，分别为核苷酸低剂量组、核苷酸中剂量组和核苷酸高剂量组，模型对照组、胰岛素治疗组、以及每小组分别10只。将试验组小鼠每日灌胃一定剂量的实施例2、4、6、7配方的复配核苷酸的生理盐水溶液+胰岛素，分别为核苷酸低剂量组45mg/kgBW+胰岛素联合用药、核苷酸中剂量组90mg/kgBW+胰岛素联合用药，和核苷酸高剂量组135mg/kgBW+胰岛素联合用药。空白对照组、模型对照组每日灌胃等量的生理 盐水溶液，胰岛素治疗组每日灌胃与核苷酸混合物+胰岛素联合用药中相同剂量的胰岛素(仅加入胰岛素，无核苷酸混合物)，30d后，取尾血测定小鼠的空腹血糖和胰岛素含量。
二、实施例1-7实验结果
1、核苷酸混合物对正常小鼠空腹血糖的影响
由表1结果可见，与对照组比较，实施例1-7中核苷酸混合物对正常小鼠空腹血糖差异无显著性，说明核苷酸混合物对正常小鼠空腹血糖无影响。
表1实施例1-7中核苷酸混合物对正常小鼠空腹血糖的影响(
Figure PCTCN2022107875-appb-000001
n＝10)
Figure PCTCN2022107875-appb-000002
2、核苷酸混合物对四氧嘧啶高血糖模型小鼠空腹血糖的影响
由表2结果可见，与空白对照组比较，模型对照组空腹血糖值显著升高(P＜0.05)，说明高血糖模型成立；与模型对照组比较，实施例1-7中各剂量核苷酸混合物对高血糖模型小鼠空腹血清胰岛素含量显著升高，血糖值显著降低(P＜0.05)，说明核苷酸混合物可以促进胰岛素的分泌，起到降低血糖的作用。
表2实施例1-7中核苷酸混合物对四氧嘧啶高血糖模型小鼠空腹血糖的影响(
Figure PCTCN2022107875-appb-000003
n＝10)
Figure PCTCN2022107875-appb-000004
Figure PCTCN2022107875-appb-000005
注： #表示与空白对照组比较，差异有统计学意义； *表示与模型对照组比较，差异有统计学意义。
3、核苷酸混合物对四氧嘧啶高血糖模型小鼠糖耐量的影响
由表3结果可见，与模型对照组比较，实施例1-7中各剂量核苷酸混合物对给葡萄糖后0.5h、2h血糖值显著降低(P＜0.05)，说明核苷酸混合物对糖尿病小鼠有升高糖耐量的作用。
表3实施例1-7中核苷酸混合物对小鼠空腹糖耐量的影响(
Figure PCTCN2022107875-appb-000006
n＝10)
Figure PCTCN2022107875-appb-000007
Figure PCTCN2022107875-appb-000008
注： #表示与空白对照组比较，差异有统计学意义； *表示与模型对照组比较，差异有统计学意义。
4、联合用药对四氧嘧啶高血糖模型小鼠降糖试验
由表4结果可见，与空白对照组比较，模型对照组空腹血糖值显著升高(P＜0.05)，说明高血糖模型成立；与模型对照组比较，胰岛素治疗组对高血糖模型小鼠空腹胰岛素含量显著升高，血糖值显著降低(P＜0.05)；与胰岛素治疗组比较，实施例2、4、6、7中各剂量核苷酸混合物与胰岛素联合用药对高血糖模型小鼠空腹胰岛素含量显著升高，血糖值降低(P＜0.05)；说明在注射的胰岛素降低血糖的同时，核苷酸混合物还可以促进胰岛素的分泌，核苷酸混合物与胰岛素起到协同降低血糖的作用。
表4实施例2、4、6、7中核苷酸混合物+胰岛素联合用药对四氧嘧啶高血糖模型小鼠空腹血糖的影响(
Figure PCTCN2022107875-appb-000009
n＝10)
Figure PCTCN2022107875-appb-000010
注： #表示与空白对照组比较，差异有统计学意义； *表示与模型对照组比较，差异有统计学意义。
实验结果表明：摄入复配核苷酸的小鼠空腹血糖值比模型对照组小鼠降低，血清胰岛素含量比模型对照组升高，并且复配核苷酸能够在一定程度上改善糖尿病小鼠的糖耐量。说明复配核苷酸及混合物可以改善机体糖耐量，促进胰岛素分泌，具有辅助治疗糖尿病的作用。

Claims (7)

  1. 一种辅助治疗糖尿病的核苷酸组合物，其特征在于，所述核苷酸组合物包括复配核苷酸，其中复配核苷酸的重量配比为：AMP 15.0-25.0％、CMP 15.0-45.0％、GMP 15.0-35.0％、UMP 15.0-30.0％。
  2. 根据权利要求1所述的核苷酸组合物，其特征在于，复配核苷酸的重量配比为：AMP 16.9％、CMP 43.2％、GMP 17.8％、UMP 22.1％，或AMP 24.3％、CMP 28.3％、GMP 19.3％、UMP 28.1％。
  3. 根据权利要求1或2所述的核苷酸组合物，其特征在于，还包括营养素或功能性物质；
    所述复配核苷酸与营养素的重量配比为：复配核苷酸8-232份、维生素A 0.16-0.9份、维生素D 0.003-0.012份、维生素E 3.18-7.15份、维生素K 1 0.018-0.04份、维生素B 1 0.34-0.76份、维生素B 2 0.34-0.76份、维生素B 6 0.34-0.76份、维生素B 12 0.0005-0.0011份、烟酸0.84-1.89份、叶酸0.09-0.2份、泛酸1.17-2.63份、维生素C 21.76-48.96份、生物素0.008-0.019份、钠334.71-522.99份、钾451.86-706.04份、铜0.18-2份、镁73.64-115.06份、铁3.3-9.2份、锌1.67-8.36份、锰0.1-2.4份、钙217.56-339.94份、磷160.67-251.04份、碘0.027-0.042份、氯251.03-870.25份、硒0.013-0.089份，所述营养素还包括铬、牛磺酸、膳食纤维中的一种或多种，铬0.0067-0.2228份、牛磺酸32.2-80.4份、膳食纤维5023-18846份；
    所述复配核苷酸与功能性物质的重量配比为：复配核苷酸1-3份、功能性物质5-15份，所述功能性物质为抗性糊精、牛磺酸、亚麻酸微囊粉、川陈皮素中的一种或多种。
  4. 如权利要求1-3任一项所述的核苷酸组合物的制备方法，其特征在于，将各组分按配方进行称量，混合均匀后制成成品。
  5. 根据权利要求4所述的制备方法，其特征在于，所述成品状态包括粉剂、颗粒剂、片剂、丸剂、口服液、胶囊。
  6. 如权利要求1-3任一项所述的核苷酸组合物在制备辅助治疗糖尿病的产品中的应用。
  7. 根据权利要求6所述的应用，其特征在于，所述产品为药品、特医食品、保健品和功能性食品。
PCT/CN2022/107875 2021-07-27 2022-07-26 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用 WO2023005911A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110853073.5A CN113616667B (zh) 2021-07-27 2021-07-27 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用
CN202110853073.5 2021-07-27

Publications (1)

Publication Number Publication Date
WO2023005911A1 true WO2023005911A1 (zh) 2023-02-02

Family

ID=78381216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/107875 WO2023005911A1 (zh) 2021-07-27 2022-07-26 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN113616667B (zh)
WO (1) WO2023005911A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616667B (zh) * 2021-07-27 2023-03-28 陈玉松 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用
CN115227706B (zh) * 2022-06-08 2023-12-29 陈玉松 5’-单磷酸核苷酸组合物在制备消脂减肥功能食品和药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1077629A (zh) * 1993-03-27 1993-10-27 颜怀玮 多核苷酸营养素产品及制造方法
CN1739571A (zh) * 2005-09-02 2006-03-01 颜怀玮 防治胰岛素依赖型糖尿病药食兼用营养素及制造方法
CN101401649A (zh) * 2008-11-17 2009-04-08 珍奥集团股份有限公司 可增强机体免疫力的组合物
CN113616667A (zh) * 2021-07-27 2021-11-09 大连珍奥生物技术股份有限公司 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048400C (zh) * 1994-05-19 2000-01-19 颜怀玮 维生素微量元素嘌呤嘧啶双核苷酸营养素产品及制造方法
CN102883626A (zh) * 2009-11-25 2013-01-16 雀巢产品技术援助有限公司 包括高蛋白质成分和外源性核苷酸的营养组合物
CN105982074A (zh) * 2015-03-06 2016-10-05 内蒙古伊利实业集团股份有限公司 核苷酸组合物及其在食品中的应用
CN106265716A (zh) * 2015-05-19 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗糖尿病中的应用
CN112056402A (zh) * 2020-08-06 2020-12-11 长沙重链抗体研究院 一种具有辅助降血糖功能的调制骆驼乳粉
CN112772917A (zh) * 2021-02-05 2021-05-11 浙江宏康生物科技股份有限公司 一种辅助治疗糖尿病的抗氧化全营养粉

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1077629A (zh) * 1993-03-27 1993-10-27 颜怀玮 多核苷酸营养素产品及制造方法
CN1739571A (zh) * 2005-09-02 2006-03-01 颜怀玮 防治胰岛素依赖型糖尿病药食兼用营养素及制造方法
CN101401649A (zh) * 2008-11-17 2009-04-08 珍奥集团股份有限公司 可增强机体免疫力的组合物
CN113616667A (zh) * 2021-07-27 2021-11-09 大连珍奥生物技术股份有限公司 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用

Also Published As

Publication number Publication date
CN113616667B (zh) 2023-03-28
CN113616667A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
WO2023005911A1 (zh) 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用
CN1272790A (zh) 用含羟基柠檬酸、肉碱和丙酮酸促进剂的组合物促进体重和脂肪降低的方法
CN101239069A (zh) 可提供活性甲基或参与甲基转移的化合物的应用
WO2023005265A1 (zh) 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用
CN101181289A (zh) 一种13种复合维生素注射剂及其生产工艺
WO2016197889A1 (zh) 复合维生素组合物在制备促进胃肠系统动力的药物中的用途
EP1198994B1 (en) Health food products
US20070218126A1 (en) Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis
TW200812594A (en) Medicine for prevention of and/or recovery from fatigue
NO20001717L (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
US20050163874A1 (en) Data analysis method
CN108904596B (zh) 一种具有改善记忆力功效的组合物
CN105982921A (zh) 一种治疗痛风的组合物及其应用
CN101229218B (zh) 用于治疗糖尿病的钒复方组合物及其制造方法
US7998500B2 (en) Nutritional supplement for women
CN108079000A (zh) 一种治疗糖尿病的药物组合物及其制备方法
CN115177732B (zh) 一种辅助预防、缓解痛风的组合物
CN110403945B (zh) 促进胃肠系统动力的复合维生素组合物及其制备方法
CN107595829B (zh) 一种防治肾性骨营养不良的组合物
CN115702933B (zh) 一种用于辅助降低血糖的组合物
CN101491584A (zh) 一种具有降血糖功能的组合物及其制备方法
CN101721421A (zh) 一种治疗肥胖症的鼻腔鼻窦用药及其制备方法
CN114847486A (zh) 一种含灵芝提取物多种维生素片的制作方法
WO2019206107A1 (zh) 促进胃肠系统动力的复合维生素组合物及其制备方法
CN116407551A (zh) 一种含有nmn的药物组合物、颗粒、微胶囊及其制备方法与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22848516

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE